377 related articles for article (PubMed ID: 956655)
1. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components.
Hammer CH; Abramovitz AS; Mayer MM
J Immunol; 1976 Sep; 117(3):830-4. PubMed ID: 956655
[TBL] [Abstract][Full Text] [Related]
2. Reaction of an activated complex of guinea-pig complement components, C56, with unsensitized erythrocytes and with erythrocytes carrying C3b molecule.
Tamura N; Baba AS
Immunology; 1976 Jul; 31(1):151-8. PubMed ID: 1027719
[TBL] [Abstract][Full Text] [Related]
3. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
4. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
5. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
6. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
7. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
8. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
10. Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5.
Goldlust MB; Shin HS; Hammer CH; Mayer MM
J Immunol; 1974 Sep; 113(3):998-1007. PubMed ID: 4213402
[No Abstract] [Full Text] [Related]
11. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
Hu VW; Shin ML
J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
[TBL] [Abstract][Full Text] [Related]
12. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
13. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
14. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of C56-initiated lysis by cell-bound C3 fragments: evidence for a mechanism independent of the prior binding of C56 to C3b.
Yamamoto KI; Lint TF; Gewurz H
J Immunol; 1977 Oct; 119(4):1346-50. PubMed ID: 894040
[TBL] [Abstract][Full Text] [Related]
16. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9.
Puentes SM; Da Silva RP; Sacks DL; Hammer CH; Joiner KA
J Immunol; 1990 Dec; 145(12):4311-6. PubMed ID: 2147941
[TBL] [Abstract][Full Text] [Related]
17. Activation of therminal components of human complement by a trypsin-activated complex of human factor B and cobra venom factor.
Miyama A; Kato T; Minoda I; Ueda T; Kashiba S
Jpn J Microbiol; 1976 Dec; 20(6):507-16. PubMed ID: 1035353
[TBL] [Abstract][Full Text] [Related]
18. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
19. On the mechanism of cytolysis by complement: evidence on insertion of C5b and C7 subunits of the C5b,6,7 complex into phospholipid bilayers of erythrocyte membranes.
Hammer CH; Nicholson A; Mayer MM
Proc Natl Acad Sci U S A; 1975 Dec; 72(12):5076-80. PubMed ID: 1061092
[TBL] [Abstract][Full Text] [Related]
20. Receptors on guinea-pig erythrocytes specific for cell-bound fourth component of human complement (C4).
Wilson AB; Prichard-Thomas S; Lachmann PJ; Coombs RR
Immunology; 1980 Feb; 39(2):195-202. PubMed ID: 7380467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
